ABEO at a glance
ABEONA THERAPEUTICS INC. (ABEO, SEC CIK 318306) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ABEONA THERAPEUTICS INC. (ABEO) reported revenue of $5.8 million (up 37.1% from FY2024) and net income of $71.2 million. Diluted EPS was $1.01.
- The most recent insider open-market purchase reported on Form 4 was by Charles Faith L. on November 13, 2026 of 15,000 shares at $2.29 per share.
- In the last 90 days, ABEO insiders reported 1 open-market purchase ($34K) and 5 open-market sales ($296K) on Form 4, a net sale of $262K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $5.8M
- +37.1% vs prior year
- Insiders · 90 days
- 1 buy · 5 sells
- Net −$262K
- Latest 8-K
- Nov 9, 2026
- Item 2.01 · Item 1.01 · Item 3.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added financing risk: November 6 private placement expected to issue 6,400,000 shares and 1,600,043 pre-funded warrants
- Most material update, commercial risk: ZEVASKYN revenue reached $33.591 million, but manufacturing, 84-hour shelf-life, and treatment-center execution remain critical
- Regulatory risk: FDA approval of Ultragenyx’s ABO-102 in September 2026 creates royalty eligibility, but payments remain subject to sales-based constraints
- Operational risk: APT-1011 acquisition adds an EoE development program requiring FDA approval before $30 million milestone eligibility
- Liquidity risk: cash and equivalents declined to $66.284 million, with $11.111 million debt principal due by December 31, 2027
Management Discussion & Analysis
- Q3 revenue $13.5M, versus $0 YoY, entirely from ZEVASKYN product sales
- Q3 operating loss $13.0M vs $24.0M, operating margin -96.3% vs not meaningful
- ZEVASKYN, sole product line, generated $13.5M revenue and $5.7M cost of sales
- Cash resources $134.9M at September 30, 2026, operating cash outflow $45.6M through nine months
- Outlook: cash sufficient through next 12 months, additional funding potentially needed for development and commercialization
AI summary of the ABEO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.01: Completion of Acquisition or Disposition of Assets
- Item 2.01 contains no separate transaction details
- Acquisition or disposition terms are incorporated from Item 1.01
Item 1.01: Entry into a Material Definitive Agreement
- Acquired APT-1011, a Phase 3-evaluated EoE candidate, for $20 million in stock with no upfront cash payment
- Issued Ellodi 4,494,383 shares, creating immediate dilution and potential future selling pressure after staggered lock-up releases
Item 3.02: Unregistered Sales of Equity Securities
- Item 3.02 links an unregistered equity issuance to the financing or transaction described in Item 1.01
- Investor impact depends on Item 1.01 terms, including securities issued, pricing, dilution and investor rights
Item 7.01: Regulation FD Disclosure
- November 9, 2026 press release announced the Transaction, with terms in Exhibit 99.1
- Investor presentation, “APT-1011 Clinical Development History,” provides supporting clinical-development context in Exhibit 99.2
Item EX-99.1: Item EX-99.1
- Acquired ABO-801, a Phase 3-ready oral EoE candidate, for $20 million in Abeona equity with no upfront cash
- Prior Phase 3 studies missed co-primary symptom endpoints, though endoscopic measures improved significantly
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announcement for quarter ended September 30, 2026
- Press release issued November 9, 2026, with results and management commentary in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Investor presentation disseminated November 9, 2026, providing updated corporate and pipeline information
- Exhibit 99.2 contains the presentation, the primary source for details on programs, milestones and strategy
Item EX-99.1: Item EX-99.1
- Q3 ZEVASKYN revenue $13.5M, up 18% sequentially, confirming early commercial traction
- 15 treatments completed since launch, with six in Q3 and eight QTC sites activated
Item 7.01: Regulation FD Disclosure
- Updated investor presentation for H.C. Wainwright’s 28th Annual Global Investment Conference on September 15, 2026
- Presentation likely provides current corporate, clinical and strategic updates relevant to investor expectations
AI summaries of ABEO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ABEO
Don't miss the next ABEO filing
- Alerts as it files. A push when ABEO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ABEO, by share count.
- Ask anything. An AI agent that reads every ABEO filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Charles Faith L. | Buy | Nov 13, 2026 | 15,000 | $2.29 |
| Vazzano Joseph Walter | Sell | Sep 29, 2026 | 9,191 | $5.16 |
| Seshadri Vishwas | Sell | Sep 29, 2026 | 19,608 | $5.16 |
| Vasanthavada Madhav | Sell | Sep 29, 2026 | 4,902 | $5.16 |
| O'Malley Brendan M. | Sell | Sep 29, 2026 | 6,727 | $5.16 |
| Alvino Mark | Sell | Sep 1, 2026 | 15,000 | $5.86 |
| Vazzano Joseph Walter | Sell | Jul 21, 2026 | 1,478 | $6.53 |
| Seshadri Vishwas | Sell | Jul 9, 2026 | 67,971 | $6.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.2M | $5.8M |
| Operating Income | - | -$64.2M | -$89.4M |
| Net Income | -$54.2M | -$63.7M | $71.2M |
| Op. Margin | - | -1512.3% | -1536.9% |
| Net Margin | - | -1501.0% | 1223.1% |
| Balance Sheet | |||
| Total Assets | $64.0M | $108.9M | $219.6M |
| Equity | - | $44.0M | $159.2M |
| ROE | - | -144.7% | 44.7% |
| Per Share | |||
| EPS | $-2.53 | $-1.55 | $1.01 |
| Cash Flow | |||
| Operating CF | - | -$56.0M | -$76.3M |
| CapEx | $331K | $2.4M | $8.0M |
Source: XBRL data in ABEONA THERAPEUTICS INC. (ABEO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
ABEO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 4 | Jul 22, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ABEO SEC filings: frequently asked questions
Are ABEO insiders buying or selling?
In the last 90 days, ABEONA THERAPEUTICS INC. (ABEO) officers, directors and 10% owners reported 1 open-market purchase worth $34,349 by 1 insider and 5 open-market sales worth $296,397 by 5 insiders on Form 4, a net sale of $262,048. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was ABEO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ABEONA THERAPEUTICS INC. (ABEO) reported revenue of $5.8 million (up 37.1% from FY2024) and net income of $71.2 million. Diluted EPS was $1.01. The figures come from the XBRL data in the 10-K.
What did ABEO report in its latest 8-K?
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K on November 9, 2026 reporting Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 1.01 (Entry into a Material Definitive Agreement), Item 3.02 (Unregistered Sales of Equity Securities) and Item 7.01 (Regulation FD Disclosure). Item 2.01 contains no separate transaction details.
What are the latest ABEO SEC filings?
ABEONA THERAPEUTICS INC. (ABEO) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 16, 2026.
What is ABEO's SEC CIK number?
ABEONA THERAPEUTICS INC. (ABEO)'s SEC Central Index Key (CIK) is 318306. EDGAR lists every ABEO filing under that number.
Ask anything about ABEO
The research agent reads ABEO's filings, financials, insider trades and 13F holders, then answers with sources.